Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.10.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GS.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HG.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.323NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FU.1.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FN.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.74NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.53NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JB.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
A.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDK.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.1.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.6NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.10.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.4.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.59NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BR.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CM.5.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBDNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EB.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CN.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BG.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.576NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.325NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.22NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.521NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.378NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.206NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.28NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.77NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JN.1.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.13.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HV.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.2.3.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BM.2.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBENUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.1.4.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.3.14NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.9.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.6.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.34NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CH.1.1.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used